KemPharm, Inc.

116 articles with KemPharm, Inc.

• KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

  12/2/2020

  CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020, with the U.S. Food and Drug Administration (FDA, or the Agency) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of atten

• KemPharm Provides Update on Development Pipeline

  11/23/2020

  IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug CandidateAdded to Pipeline,Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH)

• KemPharm Reports Third Quarter 2020 Financial Results

  10/29/2020

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET

• KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

  10/22/2020

  KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in two oral presentations during the Annual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Virtual Meeting. In addition, research conducted by KemPharm’s scientific team related to patterns of abuse of

• KemPharm and Corium Expand Relationship with New Consultation Services Agreement

  10/5/2020

  KemPharm, Inc. announced that it has expanded its relationship with Corium, Inc. through a new consultation services agreement under which KemPharm will provide product development consultation services to Corium.

• KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

  9/25/2020

  KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today filed a preliminary proxy statement on Schedule 14A (the Preliminary Proxy Statement) with the U.S. Securities and Exchange Commission (SEC) to hold a special meeting of stockholders to authorize a potential reverse stock split of the Company’s common stock (the Special Meeting).

• KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

  9/10/2020

  Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment

• KemPharm to Present at Upcoming September 2020 Investor ConferencesPresentations to Highlight Corporate, Regulatory and Pipeline Advancements

  9/2/2020

  KemPharm, Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that its president and chief executive officer, Travis C.

• KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

  8/14/2020

  KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020, with the U.S. Food and Drug Administration (FDA) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of attention deficit hype

• KemPharm Reports Second Quarter 2020 Financial Results

  8/12/2020

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Corporate and Regulatory Highlights: Received Day-74 Letter for KP415 NDA; FDA has set PDUFA date of March 2, 2021 Announced that Corium, Inc., a portfolio company of GPC, will lead all commercialization activities for KP415 Announced issuance of two additional U.S. patents governing KP415 and KP484 Financial Highlights Reported Q2 2020 revenue of $6.9 million, including $5 million m

• KemPharm to Report Second Quarter 2020 Financial ResultsConference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET

  8/4/2020

  KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020. Conference Call Information: Interested participants and investors may access the conference call b

• KemPharm Issues Letter to Shareholders - June 18, 2020

  6/18/2020

  KemPharm, Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2020 Annual Meeting of Stockholders to be held on June 19, 2020.

• KemPharm Receives Day-74 Letter for KP415 NDA

  5/19/2020

  KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the Company has received a filing communication from the U.S. Food and Drug Administration (FDA), commonly known as the “Day-74 Letter.”  The Day-74 Letter stated that the New Drug Application (NDA) for KP415 is sufficiently complete to permit a substan

• KemPharm Reports First Quarter 2020 Financial Results

  5/12/2020

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its financial results for the first quarter ended March 31, 2020.

• KemPharm to Report First Quarter 2020 Financial Results

  5/6/2020

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Tuesday, May 12, 2020, 5:00 p.m. ET

• KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

  3/2/2020

  KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2)

• KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

  2/28/2020

  KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for the fourth quarter and full-year ended December 31, 2019.

• Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

  1/15/2020

  KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today

• KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

  12/18/2019

  Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date

• KemPharm Reports Third Quarter 2019 Results

  11/14/2019

  KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended September 30, 2019.